

REMARKS

Applicants respectfully point out for the record that there are typographical errors relating to identification of the compound associated with Figures 26 and 27 as set forth in the Brief Description of the Figures Section of the above-identified specification at page 5, lines 29-32.

In particular, the above-identified specification recites at page 5, lines 29-32, that:

“Figure 26 is a solid state ^{13}C NMR for carvedilol dihydrogen phosphate dihydrate (Form I). Figure 27 is a solid state ^{31}P NMR for carvedilol dihydrogen phosphate dihydrate (Form I)”.

For the sake of clarification, applicants respectfully point out that:

“Figure 26” should refer to “a solid state ^{13}C NMR for carvedilol dihydrogen phosphate **hemihydrate** (Form I).” and

“Figure 27” should refer to “a solid state ^{31}P NMR for carvedilol dihydrogen phosphate **hemihydrate** (Form I)”;

Support to show that the aforementioned typographical errors were made are found throughout the instant specification, which defines that the compound carvedilol dihydrogen phosphate hemihydrate is **Form I** (see above-identified specification at page 4, lines 1-23, which correspond to Figures 1-8; at page 9, lines 9-13; Example 1 at page 14, lines 25-31 to page 15, lines 1-2; and Example 7, at page 16, lines 1-27 to page 17, lines 1-26).

In addition, Figures 26 and 27 are discussed in the specification as it relates to Example 7 entitled: “ ^{13}C and ^{31}P Solid State NMR Data Analysis of Carvedilol Dihydrogen Phosphate Hemihydrate (Form I)” (see, above-identified specification at page 16, lines 1-27 to page 17, lines 1-26). The above-identified specification only recites ^{13}C and ^{31}P Solid State NMR Data and/or spectrum for the compound carvedilol dihydrogen phosphate hemihydrate (Form I). Example 7 specifically refers to the fact that Figure 26 shows the ^{13}C spectrum and Figure 27 shows the ^{31}P spectrum, respectively, of carvedilol dihydrogen phosphate hemihydrate (Form I) (see, above-identified specification at page 17, lines 16-22).

This Supplemental Response has been filed merely to identify and point out the above-identified typographical errors.

In light of the foregoing, no amendments to the above-identified specification have been filed. No new matter has been added to the claims or specification by amendment.

CONCLUSION

In view of the above, applicants request consideration of the above-identified remarks.

Applicants believe that the claims of the present application are in condition for allowance and is earnestly solicited. Applicants respectfully request that a timely Notice of Allowance be issued in the present application.

If any additional fees or charges are required authorization is hereby granted to charge any necessary fees to Deposit Account No. 19-2570 accordingly.

Should the Examiner have any questions or wish to discuss any aspect of this case, the Examiner is encouraged to call the undersigned attorney at the number below.

Respectfully submitted,



Grace C. Hsu
Attorney for Applicant
Registration No. 51,336

GLAXOSMITHKLINE
Corporate Intellectual Property
UW2220 - P.O. Box 1539
King of Prussia, PA 19406-0939
Phone: (610) 270-4650
Fax: (610) 270-5090
n:\gch\P51365 - office action.doc